What is the address of CARDIOFT?

The registered office of CARDIOFT is located at Jan van Eyckplein 9, 8000 Brugge.

Is CARDIOFT still active?

Yes. According to the CBE (30 October 2026) CARDIOFT is active, legal situation “Normale toestand”, started on 7 February 2017.

Is CARDIOFT registered on Peppol?

Yes, CARDIOFT is registered on the Peppol network with ID 0208:0670804092.

What is the enterprise number of CARDIOFT?

The enterprise number of CARDIOFT is BE0670804092.

When was CARDIOFT founded?

CARDIOFT was founded on 7 February 2017.

Who are the directors of CARDIOFT?

According to the 2025 annual accounts, the directors of CARDIOFT are: Charlotte Renier, Philippe Debonnaire.

Is CARDIOFT a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 7 February 2017; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did CARDIOFT make in 2025?

CARDIOFT posted a profit after taxes of € 911,326 in financial year 2025.

What is the revenue of CARDIOFT?

As a small company, CARDIOFT is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 1,440,134.

CARDIOFT (Private Limited) - Brugge - BE0670804092

Q: What does CARDIOFT do?

CARDIOFT is registered with the CBE as active in: Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies. Private Limited, started on 7 February 2017, 1 establishment.

Dossier CARDIOFT, printed on 30 October 2026 from databakkes.be/en/0670804092/cardioft. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 22 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

CARDIOFT from Brugge, company number BE0670804092, closed financial year 2025 with a result of € 911,326 after tax. For that financial year CARDIOFT recorded a gross margin of € 1.4 million and equity of € 229,926. Compared with financial year 2024, the result moved from € 693,009 to € 911,326. Profitable, and profit is growing. The buffer shrank hard: equity is 93 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 14, 2026.

What it is worth Shrank hard

€ 229,926

▼ 93% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 911,326

▲ 32% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 460,708

▼ 48% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 3.8 million paid out

More than the year’s profit went to the shareholders; reserves fell.

Debts at end 2025

Bank debt ≈ 7 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 1.3 million

▼ 12% vs 2024

€ 180,574 is repaid this year. At this pace the long-term loan is gone in ≈ 7 years.

Owed to suppliers

€ 8,869

▲ 48% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 9,859

▲ 261% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 1,120,652 Gross margin 2022: € 1,120,652 First fiscal year in the series	€ 1,285,423 Gross margin 2023: € 1,285,423 ▲ 15% vs 2022 (€ 1,120,652) Favourable step	€ 1,260,247 Gross margin 2024: € 1,260,247 ▼ 2% vs 2023 (€ 1,285,423) Unfavourable step	€ 1,440,134 Gross margin 2025: € 1,440,134 ▲ 14% vs 2024 (€ 1,260,247) Favourable step	▲ 14%
Profit after taxes	€ 562,626 Profit after taxes 2022: € 562,626 First fiscal year in the series	€ 639,710 Profit after taxes 2023: € 639,710 ▲ 14% vs 2022 (€ 562,626) Favourable step	€ 693,009 Profit after taxes 2024: € 693,009 ▲ 8% vs 2023 (€ 639,710) Favourable step	€ 911,326 Profit after taxes 2025: € 911,326 ▲ 32% vs 2024 (€ 693,009) Favourable step	▲ 32%
Equity	€ 1,820,802 Equity 2022: € 1,820,802 First fiscal year in the series	€ 2,457,312 Equity 2023: € 2,457,312 ▲ 35% vs 2022 (€ 1,820,802) Favourable step	€ 3,150,321 Equity 2024: € 3,150,321 ▲ 28% vs 2023 (€ 2,457,312) Favourable step	€ 229,926 Equity 2025: € 229,926 ▼ 93% vs 2024 (€ 3,150,321) Unfavourable step	▼ 93%
Total debts	€ 1,759,286 Total debts 2022: € 1,759,286 First fiscal year in the series	€ 1,866,282 Total debts 2023: € 1,866,282 ▲ 6% vs 2022 (€ 1,759,286) Unfavourable step	€ 1,498,634 Total debts 2024: € 1,498,634 ▼ 20% vs 2023 (€ 1,866,282) Favourable step	€ 4,223,476 Total debts 2025: € 4,223,476 ▲ 182% vs 2024 (€ 1,498,634) Unfavourable step	▲ 182%
Cash	€ 1,253,574 Cash 2022: € 1,253,574 First fiscal year in the series	€ 906,319 Cash 2023: € 906,319 ▼ 28% vs 2022 (€ 1,253,574) Unfavourable step	€ 878,928 Cash 2024: € 878,928 ▼ 3% vs 2023 (€ 906,319) Unfavourable step	€ 460,708 Cash 2025: € 460,708 ▼ 48% vs 2024 (€ 878,928) Unfavourable step	▼ 48%
Land & buildings	€ 1,781,048 Land & buildings 2022: € 1,781,048 First fiscal year in the series	€ 2,921,049 Land & buildings 2023: € 2,921,049 ▲ 64% vs 2022 (€ 1,781,048) Unchanged	€ 3,177,433 Land & buildings 2024: € 3,177,433 ▲ 9% vs 2023 (€ 2,921,049) Unchanged	€ 3,378,354 Land & buildings 2025: € 3,378,354 ▲ 6% vs 2024 (€ 3,177,433) Unchanged	▲ 6%
Retained profit	€ 1,802,202 Retained profit 2022: € 1,802,202 First fiscal year in the series	€ 2,438,712 Retained profit 2023: € 2,438,712 ▲ 35% vs 2022 (€ 1,802,202) Favourable step	€ 3,131,721 Retained profit 2024: € 3,131,721 ▲ 28% vs 2023 (€ 2,438,712) Favourable step	€ 211,326 Retained profit 2025: € 211,326 ▼ 93% vs 2024 (€ 3,131,721) Unfavourable step	▼ 93%
Dividend	€ 3,200 Dividend 2022: € 3,200 First fiscal year in the series	€ 3,200 Dividend 2023: € 3,200 Unchanged (€ 3,200) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 3,200) Unchanged	€ 3,831,721 Dividend 2025: € 3,831,721 Unchanged (€ 0) Unchanged
Bank debt	€ 1,667,413 Bank debt 2022: € 1,667,413 First fiscal year in the series	€ 1,745,966 Bank debt 2023: € 1,745,966 ▲ 5% vs 2022 (€ 1,667,413) Unfavourable step	€ 1,474,354 Bank debt 2024: € 1,474,354 ▼ 16% vs 2023 (€ 1,745,966) Favourable step	€ 1,295,569 Bank debt 2025: € 1,295,569 ▼ 12% vs 2024 (€ 1,474,354) Favourable step	▼ 12%
Balance sheet total	€ 3,580,088 Balance sheet total 2022: € 3,580,088 First fiscal year in the series	€ 4,323,595 Balance sheet total 2023: € 4,323,595 ▲ 21% vs 2022 (€ 3,580,088) Unchanged	€ 4,648,955 Balance sheet total 2024: € 4,648,955 ▲ 8% vs 2023 (€ 4,323,595) Unchanged	€ 4,453,402 Balance sheet total 2025: € 4,453,402 ▼ 4% vs 2024 (€ 4,648,955) Unchanged	▼ 4%

Key figures of CARDIOFT, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to CARDIOFT?

What happened at CARDIOFT in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 14, 2026 New annual accounts for financial year 2025: profit of € 911,326 (▲ 32% vs 2024). Source: NBB ↗
Feb 7, 2017 New establishment in Brugge. KBO
2017 Charlotte Renier became a director. NBB
2017 Philippe Debonnaire became a director. NBB
Feb 7, 2017 Start of the company according to the CBE. KBO

In short

From € 562,626 profit in 2022 to € 911,326 profit in 2025.

Paid € 924,162 in corporate taxes since 2022.

Best year ever: 2025, with € 911,326 profit.

Paid out € 3.8 million in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Charlotte Renier Philippe Debonnaire

CARDIOFT

CATHLAB

Behind CARDIOFT are Charlotte Renier and Philippe Debonnaire. Philippe Debonnaire is also behind CATHLAB.

Directors

According to the 2025 annual accounts

Charlotte Renier

Director

since 2017

Philippe Debonnaire

Director

Also active at: CATHLAB

since 2017

Establishments

Establishment units

Physical locations of this company

Registered office

Jan van Eyckplein 9

8000 Brugge

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

Renier

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0670.804.092

VAT number

BE 0670.804.092

Registered office

Jan van Eyckplein 9, 8000 Brugge

Names & denominations

CARDIOFT

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

7 February 2017

Peppol

Active · Active since 5 Nov 2025

Activities · NACE

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

Verhuur en exploitatie van eigen of geleased residentieel onroerend goed, exclusief sociale woningen

Activiteiten van medisch specialisten

Overige vormen van onderwijs

View on CBE Public ↗ Annual accounts (NBB) ↗

CARDIOFT

Warning lights

Financials

What happened to CARDIOFT?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions